Skip to content

Down Syndrome Obstructive Sleep Apnea

Randomized Control Trial of Oxygen Therapy in Children and Adolescents With Down Syndrome and Obstructive Sleep Apnea

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06043440
Acronym
DOSA
Enrollment
230
Registered
2023-09-21
Start date
2023-10-24
Completion date
2027-12-30
Last updated
2025-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Down Syndrome, Obstructive Sleep Apnea

Brief summary

The purpose of this study is to assess whether oxygen supplementation during sleep improves working memory and other clinical and patient-reported outcomes among children who have Down Syndrome (DS) with moderate to severe Obstructive Sleep Apnea (OSA).

Detailed description

This will be a randomized, single-blind 6-month Phase-2 clinical trial that compares the impact of oxygen therapy during sleep on measures of cognition, behavior, quality of life, cardiac structure and function, and sleep in children with Down Syndrome(DS) with moderate to severe obstructive sleep apnea. The proposed study will involve participation of children and their caregivers. Children will be recruited from each site's sleep clinics and laboratories, Down syndrome clinics and otolaryngology clinics. Community recruitment will be coordinated with local Down Syndrome Associations. Children who agree to participate in the study will be screened for eligibility based on history, physical examination, and review of medical records including history of congenital heart disease and Pulmonary Hypertension (PHTN), and use of Continuous Positive Airway Pressure (CPAP). Children eligible for the study are those with persistent obstructive apnea after adenotonsillectomy or children with obstructive sleep apnea without adenotonsillar hypertrophy or in situations when parents refuse adenotonsillectomy.. The enrollment PSG eligibility will be determined by central scoring of either a research Polysomnography (PSG). In addition to an oxygen titration PSG, which determines responsiveness to oxygen, participants will be asked to wear a wrist actigraph and undergo neurocognitive testing, echocardiography, physical examination, anthropometry, and venipuncture. Caregivers will complete questionnaires to assess their child's emotional, physical, social, and school functioning, sleep quality; child's behavior and cognitive function, and will complete a sleep diary that is used concurrently with their child's use of a wrist actigraph. The latter includes caregiver completion of the Behavior Rating Inventory of Executive Function (BRIEF2), a co-primary outcome. At 3 months, caregivers will complete the BRIEF2. At 6 months, all baseline studies and a PSG will be repeated. At baseline, demographic data will be collected, including information on residential address (for use in geocoding).

Interventions

DRUGOxygen

Active nocturnal oxygen concentrator

Sponsors

Children's Hospital Medical Center, Cincinnati
CollaboratorOTHER
Children's Hospital of Philadelphia
CollaboratorOTHER
Rainbow Babies and Children's Hospital
CollaboratorOTHER
University of Michigan
CollaboratorOTHER
Children's Hospital Los Angeles
CollaboratorOTHER
Children's Hospital of The King's Daughters
CollaboratorOTHER
Seattle Children's Hospital
CollaboratorOTHER
University of Southern California
CollaboratorOTHER
Brigham and Women's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
5 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

1. Ages 5.0 to 17.9 years at the time of screening 2. Children with OSA and obstructive apnea hypopnea index (OAHI) ≥5/hour. 3. Absence of clinically significant hypoxia defined as oxygen saturation \<88% for 5 minutes or episodic desaturation to 60% as these levels would otherwise identify children eligible to routinely receive oxygen. 4. Favorable response to oxygen therapy (allowing randomization) will be defined as follows: 1. Oxygen saturation nadir \>92% and 2. Decrease in obstructive index \< 5 / hour or by \> 50% from screening PSG 3. Reaching an optimum oxygen flow which is defined as the flow that achieves the lowest level of AHI with maximum CO2 level less than 65 mmHg observed for 5 consecutive minutes and or an increase in CO2 by less than 15 points above baseline. The above criteria are observed while the patient spends a minimal of 30 minutes in the supine position and at least one cycle of rapid eye movement (REM) sleep. 4. Oxygen flow required does not exceed 3.0 LPM and does not exceed a FiO2 \> 40 %. 5. Willingness to comply with all study procedures and available for duration of study. 6. At baseline the participant attempts to perform the neuropsychological tests

Exclusion criteria

1. Current CPAP use with documented compliance(\> 4 hrs/ night; \> 70% of nights). 2. Oxygen saturation \< 90% at rest during wakefulness. 3. Chronic daytime or nighttime use of supplemental oxygen. 4. Smoker in the child's bedroom. 5. Unrepaired congenital heart disease. 6. Moderate to severe pulmonary hypertension requiring treatment with oxygen and or pulmonary vasodilator. 7. Unable to participate in a PSG. 8. Individuals who develop alveolar hypoventilation with oxygen as previously defined. 9. Other severe chronic diseases determined by their provider as making them poor study candidates. 10. Enrolled or planning to enroll in another study that may conflict with protocol requirements or confound results in this trial. 11. Documented clinically significant untreated hypothyroidism 12. Children with adenotonsillar hypertrophy who are candidates for adenotonsillectomy and parents agree to the surgery.

Design outcomes

Primary

MeasureTime frameDescription
Behavior Rating Inventory of Executive Function 2 (BRIEF2) working memory scoreBaseline and 6 monthsChange from baseline in the Behavior Rating Inventory of Executive Function 2 (BRIEF2) working memory score (BRIEF2wm). The score ranges from 35-90. A higher score is a worse outcome.
Differential Ability Scales - 2nd Edition (DAS-II) T-score.Baseline and 6 monthsChange from baseline in the Differential Ability Scales - 2nd Edition (DAS-II) recognition of pictures (DAS2RoP) T-score. The score ranges from 10-90. A higher score is a better outcome.

Secondary

MeasureTime frameDescription
Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Non Verbal raw scoreBaseline and 6 MonthsChange from baseline of Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Non Verbal raw score. The score ranges from 0-34. A higher score is a better outcome.
Differential Ability Scales-2 (DAS-II) Recall of Digits Forward raw scoreBaseline and 6 MonthsChange from baseline in Differential Ability Scales-2 (DAS-II) Recall of Digits Forward raw score. The score ranges from 0-38. A higher score is a better outcome.
Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associates Learning (PAL) adjusted total errors based on stages completedBaseline and 6 MonthsChange from baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associates Learning (PAL) adjusted total errors based on stages completed
Cambridge Neuropsychological Test Automated Battery (CANTAB) Reaction Time (RTI)Baseline and 6 MonthsChange from baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Reaction Time (RTI)
Developmental Neuropsychological Assessment 2nd Edition (NEPSY-II) verbal fluency test raw scoreBaseline and 6 MonthsChange from baseline in Developmental Neuropsychological Assessment 2nd Edition (NEPSY-II) verbal fluency test raw score. Range-N/A
Observer Memory Questionnaire - Parent Form (OMQ-PF) total T-scoreBaseline and 6 MonthsChange from baseline in Observer Memory Questionnaire - Parent Form (OMQ-PF) total T-score. The score ranges from 0-135. A higher score is a better outcome.
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for subscales (Inhibit, Self-Monitor, Shift, Emotional Control, Initiate)Baseline and 6 MonthsChange from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for subscales (Inhibit, Self-Monitor, Shift, Emotional Control, Initiate).
Child Behavior Checklist (CBCL) T-scores for domains (Internalizing, Externalizing, Total Problems).Baseline and 6 MonthsChange from baseline in Child Behavior Checklist (CBCL) T-scores for domains (Internalizing, Externalizing, Total Problems).
Child Behavior Checklist (CBCL) T-scores for subscales (Attention Problems, Thought Problems, Rule-Breaking Behaviors, Aggressive Behaviors)Baseline and 6 MonthsChange from baseline in Child Behavior Checklist (CBCL) T-scores for subscales (Attention Problems, Thought Problems, Rule-Breaking Behaviors, Aggressive Behaviors)
KIDSCREEN-27 T-scoreBaseline and 6 MonthsChange from baseline in KIDSCREEN-27 T-score, including domains of: physical well-being; psychological well-being; autonomy and parent relations; social support and peers; school environment. Range-N/A
Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance T-scoreBaseline and 6 MonthsChange from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance T-score. The score ranges from 28.7-85.6. A higher score is a worse outcome.
Patient-Reported Outcomes Measurement Information System (PROMIS) sleep-related impairment T-scoreBaseline and 6 MonthsChange from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) sleep-related impairment T-score. The score ranges from 37.9-86.6. A higher score is a worse outcome.
Presence of right ventricular hypertensionBaseline and 6 MonthsPresence of right ventricular hypertension as measured by tricuspid regurgitation continuous wave peak velocity (defined as a ratio of pulmonary artery pressure / systolic arterial pressure (PAP/SAP) \>1/3); interventricular septal flattening as measured by eccentricity index (defined as systolic ratio of \>1.25)
Wechsler Intelligence Scale (WISC) for Children 5th edition (WISC-5) Cancellation raw scoreBaseline and 6 MonthsChange from baseline of Wechsler Intelligence Scale (WISC) for Children 5th edition (WISC-5) Cancellation raw score. The score ranges from 0-128. A higher score is a better outcome.
7-day actigraphy measurement of sleep efficiencyBaseline and 6 MonthsChange from baseline in 7-day actigraphy measurement of sleep efficiency
Wechsler Preschool and Primary Scale of Intelligence 4th edition (WPPSI-4) Cancellation task raw scoreBaseline and 6 MonthsChange from baseline in Wechsler Preschool and Primary Scale of Intelligence 4th edition (WPPSI-4) Cancellation task raw score (if unable to complete Wechsler Intelligence Scale 5th edition Cancellation test). The score ranges from 0-96. A higher score is a better outcome.
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Behavior Regulation Index (BRI) domain.Baseline and 6 MonthsChange from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Behavior Regulation Index (BRI) domain. The score ranges from 35-90. A higher score is a worse outcome.
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Emotional Recognition Index (ERI) domain.Baseline and 6 MonthsChange from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Emotional Recognition Index (ERI) domain. The score ranges from 35-90. A higher score is a worse outcome.
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Cognitive Regulation Index (CRI) domain.Baseline and 6 MonthsChange from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Cognitive Regulation Index (CRI) domain. The score ranges from 35-90. A higher score is a worse outcome.
7-day actigraphy measurement of time wake after sleep onsetBaseline and 6 MonthsChange from baseline in 7-day actigraphy measurement of time wake after sleep onset
7-day actigraphy measurement of sleep fragmentationBaseline and 6 MonthsChange from baseline in 7-day actigraphy measurement of sleep fragmentation
7-day actigraphy measurement of total sleep durationBaseline and 6 MonthsChange from baseline in 7-day actigraphy measurement of total sleep duration
Polysomnography (PSG) AHI parameterBaseline and 6 MonthsChange from baseline in Polysomnography (PSG) AHI parameter. The score ranges from 0- \>40. A higher score is a worse outcome.
Polysomnography (PSG) percentage time of O2 <90 % parameterBaseline and 6 MonthsChange from baseline in Polysomnography (PSG) percentage time of O2 \<90 % parameter
Polysomnography (PSG) sleep apnea associated hypoxic burden parameterBaseline and 6 MonthsChange from baseline in Polysomnography (PSG) sleep apnea associated hypoxic burden, parameter
Polysomnography (PSG) end-tidal CO2 level, parameterBaseline and 6 MonthsChange from baseline in Polysomnography (PSG) end-tidal CO2 parameter.
Polysomnography (PSG) -based measure of sleep stagesBaseline and 6 MonthsChange from baseline in Polysomnography (PSG) -based measure of sleep stages. Range- N/A
Polysomnography (PSG) -based measure of EEG power bandsBaseline and 6 MonthsChange from baseline in Polysomnography (PSG) -based measure of EEG power bands
Polysomnography (PSG) -based measure of spindle morphologyBaseline and 6 MonthsChange from baseline in Polysomnography (PSG) -based measure of spindle morphology
Polysomnography (PSG) -based measure of spindle numbersBaseline and 6 MonthsChange from baseline in Polysomnography (PSG) -based measure of spindle numbers
Polysomnography (PSG) -based measure of spindle densityBaseline and 6 MonthsChange from baseline in Polysomnography (PSG) -based measure of spindle density
Polysomnography (PSG) -based measure of slow wave oscillationsBaseline and 6 MonthsChange from baseline in Polysomnography (PSG) -based measure of slow wave oscillations
Left ventricular diastolic function as measured by Mitral E and A wave (E:A ratio)Baseline and 6 MonthsChange from baseline in left ventricular diastolic function as measured by Mitral E and A wave (E:A ratio)
Left ventricular diastolic function as measured by E wave deceleration timeBaseline and 6 MonthsChange from baseline in left ventricular diastolic function as measured by E wave deceleration time
Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Total raw scoreBaseline and 6 MonthsChange from baseline of Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Total raw score. The score ranges from 0-64. A higher score is a better outcome.
Left ventricular diastolic function as measured by Mitral lateral tissue Doppler isovolumic relaxation timeBaseline and 6 MonthsChange from baseline in left ventricular diastolic function as measured by Mitral lateral tissue Doppler isovolumic relaxation time
Left ventricular diastolic function as measured by Pulmonary vein A wave reversal durationBaseline and 6 MonthsChange from baseline in left ventricular diastolic function as measured by Pulmonary vein A wave reversal duration
Left ventricular diastolic function as measured by Left atrial volumeBaseline and 6 MonthsChange from baseline in left ventricular diastolic function as measured by Left atrial volume
Left ventricular diastolic function as measured by Mitral septal and lateral e' and a' (E/e')Baseline and 6 MonthsChange from baseline in left ventricular diastolic function as measured by Mitral septal and lateral e' and a' (E/e')
Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Verbal raw scoreBaseline and 6 MonthsChange from baseline of Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Verbal raw score. The score ranges from 0-30. A higher score is a better outcome.

Countries

United States

Contacts

Primary ContactOltion Sina
osina@bwh.harvard.edu8573407909
Backup ContactSuzie Hicks
suzanna.hicks@cchmc.org5136364944

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026